8-KOther Events

Edwards Lifesciences Corp 8-K Report (Feb 26, 2004)

Filed February 26, 2004For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on February 26, 2004, to disclose that several of its executive officers, including the CEO, plan to sell a portion of their company stock. These sales are primarily intended to cover personal loans taken out in 1999 as part of a stock incentive program from the former parent company, Baxter International Inc. The loans are set to mature in May 2004, and the current value of the Baxter shares purchased with loan proceeds is less than the outstanding loan obligations. Investors should note that the total number of Edwards shares to be sold is expected to be relatively small, representing less than the average daily trading volume and less than ten percent of the officers' collective holdings. The exact timing and volume of sales will be influenced by stock prices. Importantly, the company affirms that all executive officers will still meet their stock ownership guidelines after these sales, mitigating concerns about a complete divestment by leadership.

Key Highlights

  • 1Several Edwards Lifesciences executive officers plan to sell company shares between February 2004 and May 2004.
  • 2The primary reason for sales is to repay personal loans taken to acquire Baxter International stock in 1999, which are maturing in May 2004.
  • 3The value of the Baxter stock acquired with the loans now significantly exceeds the loan amounts.
  • 4The total number of EW shares to be sold is expected to be less than 10% of the officers' collective ownership.
  • 5Sales volume is anticipated to be below the average daily trading volume of EW shares.
  • 6All executive officers will continue to meet their required stock ownership guidelines post-sale.
  • 7The actual number of shares sold and timing will depend on stock price fluctuations for both EW and Baxter.

Frequently Asked Questions

Executives are selling stock primarily to repay personal loans taken out in 1999 to purchase Baxter International stock. These loans are maturing in May 2004, and due to the current market value of Baxter shares, the loan obligations exceed the value of the collateral.

The company states that the total number of shares to be sold is expected to be less than the average daily trading volume and less than ten percent of the officers' collective holdings. This suggests the sales are unlikely to have a major disruptive impact on the stock price.

The filing indicates that the sales are driven by the maturity of personal loans related to a historical stock incentive program from a former parent company, not by a lack of confidence in Edwards Lifesciences. Furthermore, all officers will still meet their stock ownership guidelines after the sales.

The sales are planned to occur between the filing date (February 26, 2004) and early May 2004. The exact timing and number of shares sold will depend on the stock prices of Edwards Lifesciences and Baxter International during this period.